Properties
- Form
- tableti
- Pack
- 28
What is it?
Composition: The active substance of the preparation is pantoprazole. One tablet contains 40 mg of pantoprazole (in the form of sodium sesquihydrate). Pharmacotherapeutic group: Proton pump inhibitors. Pantoprazole is a substituted benzimidazole that suppresses gastric acid secretion by acting on the proton pump of parietal cells. Pantoprazole is transformed into its active form in the secretory tubules of parietal cells, where it inhibits the enzyme H+, K+-ATPase, thereby blocking the final stage of gastric acid production. This effect is dose-dependent. Pantoprazole inhibits both basal and stimulated gastric acid secretion. In most patients, symptomatic improvement is observed after 2 weeks of treatment. Like other proton pump inhibitors and H2-receptor antagonists, pantoprazole reduces gastric juice acidity, leading to increased gastrin production, which is reversible. Since pantoprazole's interaction with the enzyme occurs bypassing cellular receptors, its effect on gastric acid secretion is independent of cellular stimulation by other substances (acetylcholine, histamine, gastrin). The preparation has the same effect when administered intravenously and orally. See blog: Pantoprazole Normon - for the treatment of gastrointestinal ulcerative diseases. Indications: • Eradication of Helicobacter pylori in combination with antibiotics in patients with peptic ulcers to reduce the recurrence rate of duodenal and gastric ulcers caused by this microorganism; • Duodenal ulcer disease; • Moderate and severe reflux esophagitis; • Zollinger-Ellison syndrome and other hypersecretory conditions. Dosage and administration: The average therapeutic dose is 40 mg per day, the maximum daily dose is 80 mg. The duration of treatment depends on the indication but should not exceed 8 weeks. Take on an empty stomach or during breakfast. When taken twice daily, the second dose is taken before dinner. Side effects: - Gastrointestinal system: diarrhea, nausea, upper abdominal pain, flatulence. - Central nervous system: headache, dizziness. - Allergic reactions: rarely - skin rash, itching, skin hyperemia, anaphylactic reactions. - Miscellaneous: myalgia, weakness, visual disturbances, very rarely liver function impairment, jaundice, photosensitization. Contraindications: - Dyspepsia of neurotic origin; - Malignant diseases of the gastrointestinal tract; - Hypersensitivity to pantoprazole; - Age under 16 years. Pregnancy and lactation: During pregnancy and lactation, pantoprazole is prescribed only when the expected benefit to the mother outweighs the potential risk to the fetus or infant. Breastfeeding should be discontinued during lactation. Special instructions: In patients with impaired liver function, the daily dose of the preparation should not exceed 20 mg. In patients with impaired kidney function, the daily dose of the preparation should not exceed 40 mg. In elderly patients, the daily dose should not exceed 40 mg. The safety and efficacy of pantoprazole in pediatric practice have not been established. The preparation is not used in children. Endoscopic control of the gastrointestinal tract for malignant diseases must be performed before and after treatment, as pantoprazole treatment may mask the symptoms of malignant diseases and hinder correct diagnosis. When taken concurrently, pantoprazole may alter the absorption of drugs whose bioavailability depends on gastric pH. Expiration date: See packaging. Storage conditions and periods: Store at a temperature not exceeding 20-25°C. Also, see: Pantopra - Pantopra 40mg Gmp 28 tablets
